CoChat
Sign Up
Cited by 141

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Spatial Memory Formation and Memory-Enhancing Effect of Glucose Involves Activation of the Tuberous Sclerosis Complex–Mammalian Target of Rapamycin Pathway

Dash, Pramod K., Orsi, Sara A., Moore, Anthony N.·2006·The Journal of Neuroscience
DOI 10.1523/jneurosci.0671-06.2006
Open this paper in CoChat — free account

Abstract

The tuberous sclerosis complex–mammalian target of rapamycin (TSC–mTOR) cascade integrates growth factor and nutritional signals to regulate the synthesis of specific proteins. Because both growth factor signaling and glucose have been implicated in memory formation, we questioned whether mTOR activity is required for long-term spatial memory formation and whether this cascade is involved in the memory-augmenting effect of centrally applied glucose. To test our hypothesis, we directly administered rapamycin (an inhibitor of mTOR), glucose, 5-aminoimidazole-4-carboxamide-1β-4-ribonucleoside (AICAR; an activator of AMP kinase), or glucose plus rapamycin into the dorsal hippocampus after we trained rats in the Morris water maze task. The results from these studies indicate that glucose enhances, whereas AICAR and rapamycin both impair, long-term spatial memory. Furthermore, the memory-impairing effect of targeted rapamycin administration could not be overcome by coadministration of glucose. Consistent with these behavioral results, biochemical analysis revealed that glucose and AICAR had opposing influences on the activation of the TSC–mTOR cascade, as indicated by the phosphorylation of ribosomal S6 kinase (S6K) and 4E binding protein 1 (4EBP1), targets of mTOR. Together, these findings suggest that memory formation requires the mTOR cascade and that the memory-enhancing effect of glucose involves its ability to activate this pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.0671-06.2006

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Intrahippocampal infusion of rapamycin decreases S6K phosphorylation. Shown are representative images of immunoreactivity for phosphorylated S6K within the CA1/CA2 subfield of the hippocampus after intrahippocampal vehicle ( A , C , E ) or rapamycin ( B , D , F ) infusion. A , B , Core of the infusion. C , D , At 1.5 mm caudal to the infusion site. E , F , Ventral hippocampus. Scale bar, 100 𝛍 m.
Figure 1 Intrahippocampal infusion of rapamycin decreases S6K phosphorylation. Shown are representative images of immunoreactivity for phosphorylated S6K within the CA1/CA2 subfield of the hippocampus after intrahippocampal vehicle ( A , C , E ) or rapamycin ( B , D , F ) infusion. A , B , Core of the infusion. C , D , At 1.5 mm caudal to the infusion site. E , F , Ventral hippocampus. Scale bar, 100 𝛍 m.CC-BY-NC-SA · From the PDF
Image 2
CC-BY-NC-SA · From the PDF
Figure 5 AICAR decreases mTOR activity and impairs long-term spatial memory. A , Representative Western blots and summary data showing that intrahippocampal administration of 260 ng of AICAR decreases phospho-S6K and phospho-4EBP1, but not total S6K or 4EBP1, immunoreactivities at 30 min after infusion as compared with the contralateral vehicle-infused hippocampus. B , Latencies during water maze training and probe trial for animals infused with either vehicle ( n = 8) or 260 ng/hippocampus AICAR ( n = 9). C , Representative probe trial traces of a vehicle-infused and an AICAR-infused animal showing the path taken before the first platform crossing. AICAR-infused animals had an increased mean distance traveled ( D ) and a decreased number of platform crossings ( E ) during the probe trial. F , Swimming speed was not different between the two groups. Data are presented as the mean ± SEM; * p < 0.05.
Figure 5 AICAR decreases mTOR activity and impairs long-term spatial memory. A , Representative Western blots and summary data showing that intrahippocampal administration of 260 ng of AICAR decreases phospho-S6K and phospho-4EBP1, but not total S6K or 4EBP1, immunoreactivities at 30 min after infusion as compared with the contralateral vehicle-infused hippocampus. B , Latencies during water maze training and probe trial for animals infused with either vehicle ( n = 8) or 260 ng/hippocampus AICAR ( n = 9). C , Representative probe trial traces of a vehicle-infused and an AICAR-infused animal showing the path taken before the first platform crossing. AICAR-infused animals had an increased mean distance traveled ( D ) and a decreased number of platform crossings ( E ) during the probe trial. F , Swimming speed was not different between the two groups. Data are presented as the mean ± SEM; * p < 0.05.CC-BY-NC-SA · From the PDF
Figure 6 Post-training administration of glucose cannot overcome the memory impairmentcausedbythecoadministration of rapamycin. A , Performance during training and testing in the water maze task for animals infused with either 0.9 ng of rapamycin/hippocampus or 0.9 ngofrapamycinplus20 𝛍 gofglucose/hippocampus.ErrorbarsindicateSEM. B , Representative photomicrograph of a cresyl violet-stained tissue section showing the infusion track in one of the cannulated animals used in the behavioral studies. C , Illustration indicating the infusion sites (black circles) for the animals used in the behavioral studies. Non-redundant infusion sites are shown.
Figure 6 Post-training administration of glucose cannot overcome the memory impairmentcausedbythecoadministration of rapamycin. A , Performance during training and testing in the water maze task for animals infused with either 0.9 ng of rapamycin/hippocampus or 0.9 ngofrapamycinplus20 𝛍 gofglucose/hippocampus.ErrorbarsindicateSEM. B , Representative photomicrograph of a cresyl violet-stained tissue section showing the infusion track in one of the cannulated animals used in the behavioral studies. C , Illustration indicating the infusion sites (black circles) for the animals used in the behavioral studies. Non-redundant infusion sites are shown.CC-BY-NC-SA · From the PDF
Image 5
CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 59

  1. 10.1007/BF02244373 · DOI
  2. 10.1146/annurev.ph.55.030193.002145 · DOI
  3. 10.1038/45287 · DOI
  4. (1998), J Neurosci, 18, 10037, 10.1523/JNEUROSCI.18-23-10037.1998 · DOI
  5. 10.1101/lm.74104 · DOI
  6. (1999), J Neurosci, 19, 3535, 10.1523/JNEUROSCI.19-09-03535.1999 · DOI
  7. 10.1113/jphysiol.2003.047019 · DOI
  8. 10.1101/lm.88205 · DOI
  9. 10.1016/S0092-8674(00)81653-0 · DOI · Paper page
  10. 10.1111/j.1432-1033.1995.tb20498.x · DOI
  11. 10.1002/hipo.20078 · DOI
  12. 10.1002/jnr.20174 · DOI
  13. 10.1089/neu.1994.11.275 · DOI
  14. 10.1038/ncb847 · DOI
  15. 10.1016/S0163-1047(86)80022-X · DOI
  16. 10.1073/pnas.82.13.4549 · DOI
  17. 10.1073/pnas.94.6.2693 · DOI
  18. 10.1073/pnas.96.26.14866 · DOI
  19. 10.1126/science.1715094 · DOI
  20. 10.1038/ncb839 · DOI · Paper page
  21. 10.1016/S0092-8674(03)00929-2 · DOI · Paper page
  22. 10.1038/ng1494 · DOI
  23. 10.1128/MMBR.69.1.79-100.2005 · DOI
  24. 10.1523/JNEUROSCI.2270-05.2005 · DOI
  25. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G (1997) Rapamycin suppresses 5′-TOP mRNA translation through inhibition of p70s6k. EMBO J 3693–3704. · DOI · Paper page
  26. 10.1006/nlme.1996.0020 · DOI
  27. (2002), Ann NY Acad Sci, 959, 167, 10.1111/j.1749-6632.2002.tb02091.x · DOI
  28. 10.1016/j.nlm.2004.10.004 · DOI
  29. 10.1523/JNEUROSCI.2284-05.2005 · DOI · Paper page
  30. 10.1210/en.2004-0968 · DOI
  31. 10.1016/S0306-4522(97)00630-1 · DOI
  32. 10.1016/j.tibs.2003.11.007 · DOI
  33. 10.1016/j.cell.2005.02.031 · DOI · Paper page
  34. 10.1016/S0092-8674(00)80484-5 · DOI
  35. 10.2337/diabetes.53.8.1953 · DOI
  36. 10.1073/pnas.050583697 · DOI · Paper page
  37. 10.1016/0166-4328(88)90022-8 · DOI
  38. 10.1074/jbc.M405173200 · DOI
  39. 10.1073/pnas.0506925102 · DOI
  40. 10.1074/jbc.275.10.7416 · DOI
  41. 10.1177/08830738040190090601 · DOI
  42. (1994), J Neurosci, 14, 7478, 10.1523/JNEUROSCI.14-12-07478.1994 · DOI
  43. 10.1073/pnas.93.10.4693 · DOI
  44. (1998), J Neurosci, 18, 1595, 10.1523/JNEUROSCI.18-04-01595.1998 · DOI
  45. 10.1016/S0166-4328(01)00242-X · DOI
  46. 10.1016/S0306-4522(01)00500-0 · DOI
  47. 10.1016/S1474-4422(02)00190-4 · DOI · Paper page
  48. (2000), J Neurosci, 20, 8177, 10.1523/JNEUROSCI.20-21-08177.2000 · DOI
  49. (1985), Exp Brain Res, 58, 11
  50. 10.1046/j.1460-9568.2003.02578.x · DOI
  51. (2000), Cancer Res, 60, 3504
  52. 10.1016/S0955-0674(98)80150-6 · DOI
  53. 10.1016/0014-5793(94)01006-4 · DOI
  54. 10.1073/pnas.012605299 · DOI · Paper page
  55. 10.1074/jbc.M303257200 · DOI
  56. 10.1146/annurev.neuro.24.1.327 · DOI
  57. 10.1046/j.1460-9568.2003.02820.x · DOI
  58. 10.1111/j.1471-4159.2005.03538.x · DOI · Paper page
  59. (2004), Curr Top Microbiol Immunol, 279, 271

Cited by

Sorted by citations

See all 141

Metadata

Authors
Dash, P. K., Orsi, S. A., & Moore, A. N.
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2006-08-02
Volume
26
Issue
31
Pages
8048-8056
ISSN
  • 0270-6474
  • 1529-2401
DOI
10.1523/jneurosci.0671-06.2006
Cited by
141
References
8
Language
en
Licence
creativecommons.org/licenses/by-nc-sa/4.0/ (vor, 184 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review